Chromogenic Assays for FIXa and FXa Activities
To evaluate FIXa activity, we conducted an enzymatic assay consisting of various concentrations of human FIXa and 4 μM phospholipids in Tris-buffered saline (50 mM Tris, 150 mM NaCl) containing 1 mM CaCl 2 and 0.1% (w/v) bovine serum albumin (BSA), and incubated for 30 minutes at room temperature. After adding a chromogenic substrate specific to FIXa (Spectrozyme FIXa; Sekisui Diagnostics), we measured absorbance at 405 nm to determine FIXa activity.
To evaluate FXa activity, we conducted an enzymatic assay consisting of various concentrations of human FXa and 4 μM phospholipids in Tris-buffered saline containing 1 mM CaCl 2 and 0.1% (w/v) BSA, and incubated for 30 minutes at room temperature. After adding a chromogenic substrate specific to FXa (S-2222; Sekisui Diagnostics), we measured absorbance at 405 nm to determine FXa activity.
To evaluate FXa inhibition, we conducted an enzymatic assay consisting of 1.25 nM human FXa, 4 μM phospholipids, various concentrations of full-length recombinant human tissue factor pathway inhibitor (TFPI; Sekisui Diagnostics), and emicizumab in Tris-buffered saline containing 1 mM CaCl 2 and 0.1% (w/v) BSA, and incubated for 30 minutes at room temperature. After adding a chromogenic substrate specific to FXa (S-2222; Sekisui Diagnostics), we measured absorbance at 405 nm to determine FXa activity.
Thrombin Generation Assay
Thrombin generation assays were performed with standard equipment and CTusing a 96-well plate fluorometer (Thermo Fisher Scientific) equipped with analyzing software (Thrombinoscope BV, Maastricht, the Netherlands). Thrombin generation was initiated with an intrinsic pathway triggering solution containing 0.04 nM human FXIa and 20 μM phospholipids in Tris-buffered saline solution containing 0.1% (w/ v) BSA, or extrinsic pathway triggering solutions (PPPReagent HIGH, PPP-Reagent LOW; Thrombinoscope BV) in normal plasma (Sysmex, Kobe, Japan) or congenital FVIIIdeficient plasma (George King Bio-Medical, Overland Park, Kansas, United States) with various concentrations of emicizumab in Tris-buffered saline solution containing 0.1% (w/ v) BSA. To initiate the reaction, 20 μL of FluCa reagent prepared from a FluCa kit (Thrombinoscope BV) was dispensed by the instrument as programmed. We analyzed the thrombograms, peak height, and lag time by the instrument's software. 
